A Multicenter, Randomized, Parallel Group, Double-blind, Phase 2 Trial to Evaluate Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
Latest Information Update: 12 Jun 2023
At a glance
- Drugs SCM CGH (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms SCM-CGH2001
- Sponsors SCM Lifescience
- 07 Jun 2023 Planned number of patients changed from 77 to 84.
- 07 Jun 2023 Planned End Date changed from 31 Dec 2022 to 30 Sep 2024.
- 07 Jun 2023 Planned primary completion date changed from 31 Mar 2022 to 31 Mar 2024.